糖尿病视网膜病变的不断变化的治疗场景
Aumer Shughoury1, Ashay Bhatwadekar1, Denis Jusufbegovic1
1Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
糖尿病视网膜病变 (DR) 治疗方法已经显著发展,抗VEGF疗法彻底改变了护理. 新兴的生物药物和新型的输送方法为这种导致失明的主要原因的持续有效管理提供了希望.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 是全球视力损失的主要原因.
- 治疗DR的治疗方法已经从垂体除到光凝和视内注射的进展.
- 血管内皮生长因子 (VEGF) 抑制剂代表了DR管理的重大进步.
研究的目的:
- 审查糖尿病视网膜病变的当前和新型治疗策略.
- 突出抗VEGF疗法和其他向治疗的进展.
- 讨论DR的创新药物输送系统.
主要方法:
- 关于传统,当代和新兴DR疗法的综合文献综述.
- 专注于抗VEGF药物,受体氨酸激酶抑制剂和血管蛋白-Tie2通路抑制剂.
- 探索整合素通路抑制剂,基因疗法和全身治疗.
主要成果:
- 通过持续释放技术进行静脉内输送,可以提高治疗的耐用性.
- 目前正在研究新型药物的非侵入性局部和全身途径.
- 针对血管新生,炎症和神经退行的一系列生物药物正在开发中.
结论:
- 对于DR的治疗环境正在迅速发展,提供了改进的治疗选择.
- 进一步的研究是必不可少的,以确认新的DR疗法的疗效和现实世界结果.
- 新的策略有望更有效和长期管理糖尿病眼病.
更多相关视频
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
04:36Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024
相关概念视频
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Angle Closure Glaucoma: Treatment
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Glaucoma: Overview
